UPDATE 1-Merck, Samsung Bioepis launch discounted U.S. Remicade alternative

NEW YORK/SEOUL, July 24 (Reuters) – Merck & Co andSouth Korea’s Samsung Bioepis Co Ltd said on Monday they havebegun selling a less expensive alternative version of Johnson &Johnson’s rheumatoid arthritis drug Remicade in theUnited States, a move that should accelerate price declines forthe big-selling medicine.
The post UPDATE 1-Merck, Samsung Bioepis launch discounted U.S. Remicade alternative appeared first on RocketNews | Top News Stories From Around the Globe.